[go: up one dir, main page]

MX2009008584A - Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer. - Google Patents

Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.

Info

Publication number
MX2009008584A
MX2009008584A MX2009008584A MX2009008584A MX2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A
Authority
MX
Mexico
Prior art keywords
combination
combinations
therapeutic agents
treating cancer
propenamide
Prior art date
Application number
MX2009008584A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Wenlin Shao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009008584A publication Critical patent/MX2009008584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación que comprende la N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)-etil]-amino]-metil]-f enil]-2E-2-propenamida; y uno o más agentes farmacéuticamente activos; a composiciones farmacéuticas que comprenden esta combinación; a métodos de tratamiento que comprenden esta combinación; a procesos para elaborar dicha combinación; y a un paquete comercial que comprende la combinación mencionada.
MX2009008584A 2007-02-15 2008-02-13 Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer. MX2009008584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89000507P 2007-02-15 2007-02-15
PCT/US2008/053798 WO2008100985A2 (en) 2007-02-15 2008-02-13 Combination of lbh589 with other therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
MX2009008584A true MX2009008584A (es) 2009-08-18

Family

ID=39560929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008584A MX2009008584A (es) 2007-02-15 2008-02-13 Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.

Country Status (21)

Country Link
US (7) US20100069458A1 (es)
EP (3) EP2491923A3 (es)
JP (1) JP2010519209A (es)
KR (1) KR20090110913A (es)
CN (1) CN101626758A (es)
AR (1) AR065335A1 (es)
AU (1) AU2008216327A1 (es)
BR (1) BRPI0807812A2 (es)
CA (1) CA2677651A1 (es)
CL (1) CL2008000470A1 (es)
CO (1) CO6220928A2 (es)
EC (1) ECSP099576A (es)
IL (1) IL200193A0 (es)
MA (1) MA31205B1 (es)
MX (1) MX2009008584A (es)
PE (1) PE20090519A1 (es)
RU (1) RU2009134223A (es)
TN (1) TN2009000344A1 (es)
TW (1) TW200848022A (es)
WO (1) WO2008100985A2 (es)
ZA (1) ZA200905159B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2117598A2 (en) * 2007-01-10 2009-11-18 Novartis AG Formulations of deacetylase inhibitors
JP2010520176A (ja) 2007-03-01 2010-06-10 ノバルティス アーゲー ５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤
CL2008002786A1 (es) * 2007-09-20 2009-05-15 Novartis Ag Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
ME02230B (me) 2009-01-08 2016-02-20 Curis Inc Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2557923A4 (en) * 2010-04-16 2013-10-23 Curis Inc TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS
CN102241628B (zh) * 2010-05-14 2015-11-25 中国人民解放军总医院 (2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
RU2013114246A (ru) * 2010-09-01 2014-10-20 Новартис Аг Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
PE20141382A1 (es) 2011-04-01 2014-11-04 Curis Inc Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zinc
WO2012149493A2 (en) * 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
NZ618367A (en) * 2011-06-14 2016-01-29 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
US20130178483A1 (en) * 2011-06-28 2013-07-11 Pharmacyclics, Inc. Methods and Compositions for Inhibition of Bone Resorption
CA2863679A1 (en) 2011-08-17 2014-05-30 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CN102949722A (zh) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 基于p38抑制剂和细胞生长因子的新颖药物组合物
WO2013070996A1 (en) 2011-11-11 2013-05-16 Novartis Ag Method of treating a proliferative disease
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
KR20160145833A (ko) * 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
TWI735413B (zh) * 2014-06-02 2021-08-11 國立陽明交通大學 抗藥性癌症之治療方法
EP3154952A4 (en) * 2014-06-10 2018-03-14 University of South Carolina Methods and compositions for treatment of her-positive cancers
MA41544A (fr) * 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
KR101941045B1 (ko) * 2017-08-09 2019-01-22 연세대학교 산학협력단 암의 예방 또는 치료용 약학적 조성물
KR101988124B1 (ko) * 2017-08-31 2019-06-11 사회복지법인 삼성생명공익재단 암 연관 섬유아세포 표적용 약학적 조성물
PE20211050A1 (es) 2018-08-10 2021-06-04 Navire Pharma Inc Inhibidores de ptpn11
CA3112177A1 (en) 2018-09-11 2020-03-19 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN115137716A (zh) * 2021-04-19 2022-10-04 海军军医大学第一附属医院第二军医大学第一附属医院上海长海医院 紫草素及其药学上可接受的盐类在制备预防或治疗绝经后骨质疏松症药物中的应用
CN118615291A (zh) * 2024-04-19 2024-09-10 三峡大学 角鲨烯环氧酶新型抑制剂及其在制备治疗抗乳腺癌的药物上的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
ATE307123T1 (de) 1998-02-25 2005-11-15 Sloan Kettering Inst Cancer Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
RU2311200C2 (ru) * 2001-11-06 2007-11-27 Новартис Аг Комбинация ингибитора циклооксигеназы-2 и ингибитора гистондезацетилазы
CN1791396A (zh) * 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
EP1667720A1 (en) * 2003-09-18 2006-06-14 Novartis AG Combination of a histone deacetylase inhibitor with a death receptor ligand
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
BRPI0614090A2 (pt) * 2005-08-03 2011-03-09 Novartis Ag uso de inibidores da hdac para o tratamento do mieloma

Also Published As

Publication number Publication date
EP2491923A3 (en) 2012-12-26
US20170027909A1 (en) 2017-02-02
EP2120900A2 (en) 2009-11-25
US20130029927A1 (en) 2013-01-31
US20180289670A1 (en) 2018-10-11
US20150094274A1 (en) 2015-04-02
CN101626758A (zh) 2010-01-13
US20170246147A1 (en) 2017-08-31
KR20090110913A (ko) 2009-10-23
TW200848022A (en) 2008-12-16
JP2010519209A (ja) 2010-06-03
CA2677651A1 (en) 2008-08-21
ZA200905159B (en) 2010-05-26
WO2008100985A3 (en) 2008-10-30
EP2359818A1 (en) 2011-08-24
US20180071251A1 (en) 2018-03-15
CL2008000470A1 (es) 2008-08-29
EP2491923A2 (en) 2012-08-29
RU2009134223A (ru) 2011-03-20
ECSP099576A (es) 2009-09-29
TN2009000344A1 (en) 2010-12-31
CO6220928A2 (es) 2010-11-19
AR065335A1 (es) 2009-06-03
MA31205B1 (fr) 2010-02-01
IL200193A0 (en) 2010-04-15
US20100069458A1 (en) 2010-03-18
AU2008216327A1 (en) 2008-08-21
PE20090519A1 (es) 2009-05-29
BRPI0807812A2 (pt) 2020-06-23
WO2008100985A2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MX2009008584A (es) Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
MX344580B (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
EA201000808A1 (ru) Индольные соединения и способы лечения висцеральной боли
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
EA200801752A1 (ru) Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
HUE057440T2 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
MX2009011949A (es) Inhibidores de proteina activadora de 5-lipoxigenasa (flap).
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MX357801B (es) Agentes dirigidos a gadd45beta.
TW200616953A (en) Indole, indazole or indoline derivatives
IN2014MN00139A (es)
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
IL204640A0 (en) Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
WO2010053861A3 (en) Biologically active amides
PE20081303A1 (es) Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
MX2010008586A (es) Amidas de acido 3-(4-fluorofenil)-3-hidroxi-2-amino-propionico y compuestos relacionados que tienen actividad analgesica.
EE200800065A (et) Prasoloprimidinoonhendit sisaldav toimeaine eesn„„rmesuurenemuse „rahoidmiseks ja raviks
AR068822A1 (es) Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso
TN2009000427A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
MY165097A (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
EA201070844A1 (ru) ((e)-n-{3-[1-(8-фтор-11h-10-окса-1-аза-дибензо[a,d]циклогептен-5-илиден)пропил]фенил}метансульфонамид) в качестве модулятора рецепторов глюкокортикоидов для лечения ревматизма

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal